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ABSTRACT
Background: Patients with severe aortic stenosis and
coexisting non-cardiac conditions may be at high risk
for surgical replacement of the aortic valve or even be
no candidates for surgery. In these patients,
transcatheter aortic valve implantation (TAVI) is
suggested as an alternative. Results of the PARTNER
(Placement of AoRTic TraNscathetER Valve) trial
comparing the clinical effectiveness of TAVI with
surgical valve replacement and standard therapy were
published. The authors assessed the cost-
effectiveness of TAVI in Belgium.
Methods: A Markov model of incremental costs,
effects (survival and quality of life) and incremental
cost-effectiveness of TAVI was developed. The impact
on survival, number of events and quality of life was
based on the PARTNER trial. Costs per event were
context speciﬁc.
Results: In high-risk operable patients, even if the
minor differences in 30-day and 1-year mortality are
taken into account, the incremental cost-effectiveness
ratio (ICER) remains on average above €750000 per
quality-adjusted life-year (QALY) gained (incremental
cost: €20400; incremental effect: 0.03 QALYs). In
inoperable patients, an ICER of €44900 per QALY
(incremental cost: €33200; incremental effect: 0.74
QALYs) is calculated, including a life-long extrapolation
of the mortality beneﬁt. This result was sensitive to the
assumed time horizon. The subgroup of anatomically
inoperable patients had better outcomes than
medically inoperable patients, with ICERs decreasing
more than €10000/QALY.
Conclusions: It is inappropriate to consider
reimbursement of TAVI for high-risk operable patients.
Reimbursing TAVI in inoperable patients in essence is
a political decision. From an economic perspective, it
would be prudent to ﬁrst target patients that are
inoperable because of anatomical prohibitive
conditions. In the search for evidence, the authors
identiﬁed non-published negative results from
a randomised controlled TAVI trial. The study sponsor
should be more willing to share this information to
allow balanced evaluations and policy
recommendations. Payers should require these data
before taking reimbursement decisions.
BACKGROUND
Degenerative aortic stenosis is a common
valvular heart disease, mostly affecting elderly
people. Since many of those patients suffer
from comorbidities, they might not be
amenable to surgical valve replacement. In
this context, transcatheter aortic valve
implantation (TAVI), a less invasive approach
to correct the valvular stenosis, has been
developed. Until recently, the assessment of
the clinical effectiveness of TAVI had to rely
on reports from uncontrolled case series,
making it prone to bias. The randomised
controlled PARTNER (Placement of AoRTic
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- To assess the cost-effectiveness of transcatheter
aortic valve implantation (TAVI) for Belgian
patients.
Key messages
- In high-risk operable patients, surgical aortic
valve replacement and TAVI are associated with
similar mortality rates at 1 year. However, there
is a twice as high rate of stroke after TAVI. From
an economic point of view, the less invasive
nature of the TAVI procedure does not weigh
against the extra costs of about €20000 per
patient.
- In inoperable patients, TAVI signiﬁcantly reduces
the rate of death from any cause as compared
with a non-surgical approach. The ICER is about
€45000 per QALY gained. Nevertheless,
a distinction should be made between inoper-
ability for anatomic versus medical reasons. TAVI
offers more value for money in the former patient
group with ICERs decreasing more than €10000
per QALY.
- If policy makers are willing/able to pay the
relative high price for TAVI, it is advised to focus
in the ﬁrst place on the anatomic inoperable
patients.
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Open Access ResearchTraNscathetER Valve) trial (NCT00530894) provided
more robust data,
1 2 allowing to more reliably estimate
the clinical beneﬁt of TAVI as compared with other
treatment modalities. After the publication of the pivotal
trial results, additional data from the PARTNER trial
became available. Among them are non-published
negative mortality data from the Continued Access study,
related to patients treated according to the randomised
protocol for inoperable patients. We used the available
trial data to be incorporated in a health economic model
in order to calculate TAVI’s cost-effectiveness. This is of
major importance to support rational reimbursement
decisions, taking into account the ﬁnancial constraints.
METHODS
A Markov simulation model is developed in Excel in
order to assess the efﬁciency of TAVI. Having a possible
impact on both mortality and quality of life (QoL), both
cost-effectiveness (with outcomes expressed in life-years
gained (LYG)) and cost-utility analyses (with LYG
adjusted for QoL) are performed. The @Risk add-in tool
is used for probabilistic modelling and probabilistic
sensitivity analyses.
The analysis includes direct healthcare costs from the
perspective of the healthcare payer.
3 Payments out of the
public healthcare budget as well as patients’ co-payments
are included. Since baseline employment rates are
expected to be low in the target population, indirect
productivity costs are ignored.
Population
The model simulates a hypothetical cohort of 1000 TAVI-
eligible patients. The type of participants considered
reﬂects the PARTNER patients. The PARTNER study
incorporated two parallel prospective, multicenter,
randomised, active-treatment-controlled clinical trials.
1
Patients were divided into two cohorts: those who were
considered to be candidates for surgery but at high
surgical risk (cohort A) and those who were no suitable
candidates for surgery (cohort B) (see ﬁgure 4 in the
supplementary appendix). In the ﬁrst cohort, TAVI
could be performed transfemoral or transapical. The
average age was 84 and 83 years in high-risk operable
and inoperable patients, respectively. The proportion of
men was 57% and 46%, respectively.
12This is reﬂected
in the model and taken into account when extrapolating
the short-term results into lifetime outcomes. More
information on the PARTNER study design is available in
the supplementary appendix.
Intervention and comparator
The Edwards SAPIEN heart-valve system (Edwards Life-
sciences) is used in the PARTNER study. The comparator
is different for the two cohorts. In the high-risk operable
patients, this is surgical aortic valve replacement (AVR).
In the inoperable patients, the comparator treatment
was a so-called standard therapy incorporating a balloon
valvuloplasty in most patients.
Time horizon
There was no signiﬁcant difference in survival after
1 year in the high-risk operable patients. Therefore, in
our model, the time horizon is restricted to this period.
In inoperable patients, there is a survival advantage after
1 year, and survival data are extrapolated to a lifetime
time horizon. Future costs and beneﬁts are discounted at
a yearly rate of 3% and 1.5%, respectively.
3
Markov model
A Markov model with monthly cycles is set up (ﬁgure 1).
The square node points at the choice between TAVI and
the alternative intervention (AVR in high-risk operable
patients (cohort A) or standard therapy in inoperable
patients (cohort B)). In every cycle, the patient can die
(end node), be hospitalised, have an adverse event or no
event.
Mortality
The PARTNER study is the ﬁrst randomised controlled
trial (RCT) to assess the safety and efﬁcacy of the
Sapien valve. It was conducted under the auspices of
the Food and Drug Administration (FDA) and required
to apply for market approval for the valve on the US
market. In addition to published study results, informa-
tion was searched in FDA’s Advisory Panel documents,
conference documents and press releases, and from the
study sponsor.
Table 1 shows the 30-day and 1-year mortality rates in
the PARTNER trial. Intention-to-treat results are imple-
mented in the model. In high-risk operable patients, the
non-inferiority study showed non-signiﬁcant differ-
ences.
2 In inoperable patients, an absolute 20%
mortality risk reduction is found after 1 year.
1 In
ARTICLE SUMMARY
Strengths and limitations of this study
- Hospital billing data of 183 Belgian patients treated with the
Edwards SAPIEN valve were at our disposal for cost
calculations.
- Next to the published pivotal PARTNER (Placement of AoRTic
TraNscathetER Valve) trial, a non-published randomised
controlled trial (RCT) with TAVI was identiﬁed. This Continued
Access trial was performed according to the same study
protocol of the pivotal PARTNER trial. The mortality outcomes
of this Continued Access RCT, disfavouring TAVI, were
included in our analysis.
- An unbalance in patient characteristics was observed in the
inoperable patients of the PARTNER trial, favouring the TAVI
group. A subgroup analysis showed a greater improvement for
anatomic inoperable patients versus those inoperable for
medical reasons.
- The most important limitation of our analysis is the non-
availability of all relevant study outcomes, especially for the
negative non-published Continued Access RCT. The study
sponsor should be willing to reveal this information in due
time. Payers should require access to these non-published data
before deciding on reimbursement.
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following the same protocol, presented an absolute
12.7% higher mortality in the TAVI group.
4 The
weighted average results in an absolute mortality reduc-
tion by TAVI of 12.3%, which is used in the reference
case. A validity check was applied to check whether the
modelled 1-year mortality rates were consistent with the
published rates.
The monthly mortality rate between the second month
and 1 year is deducted from the 1-month and 1-year
mortality and is assumed to be constant over this period.
This monthly mortality rate increases yearly according to
the age- and sex-speciﬁc mortality rates of the total
Belgian population to extrapolate trial results to the
lifetime time horizon for inoperable patients.
Utilities
The PARTNER study protocol mentions QoL was
measured with the EQ-5D questionnaire in both the
high-risk operable and inoperable patients. This generic
utility measure was applied both at baseline and after 1, 6
and 12 months. Results were not published but provided
by the study sponsor for inoperable patients and
included in the model (details are provided in table 3 in
the supplementary appendix). An adjustment for base-
line QoL differences was included. We assumed a linear
QoL evolution between baseline, 1, 6 and 12 months and
a constant QoL afterwards.
Unfortunately, although requested from the study
sponsor, no EQ-5D results were provided for high-risk
operable patients. At 30 days, more patients in the
transcatheter group than in the surgical group had
a reduction in symptoms to NYHA class II or lower
(p<0.001). Among patients who could perform a 6 min
walk test, patients in the transcatheter group walked
farther than those in the surgical group (p¼0.002).
2
Therefore, a similar difference as observed during the
ﬁrst month in inoperable patients was assumed. The
NYHA functional class was no longer different at
6 months. At 1 year, there were no signiﬁcant between-
group differences in cardiac symptoms and the 6 min
walk distance.
2 Therefore, in the base case, no further
differences in QoL were included in the model for high-
risk operable patients. This assumption was altered in
a sensitivity analysis.
Costs
To calculate incremental costs (ICs), the initial cost
differences between TAVI and AVR during hospital-
isation (high-risk operable patients) and between TAVI
and standard therapy (inoperable patients) are taken
into account. Second, events with a possible incremental
impact were selected from the published PARTNER trial.
Included events are repeat hospitalisations, minor/
major stroke and TIA, and cardiac reintervention.
Vascular complications and major bleedings are not
separately included to avoid double counting since these
mainly occur during the initial or repeat hospitalisation.
The percentage of events observed in the PARTNER trial
is provided in the supplementary appendix (table 4).
Only results for the pivotal trial were published and thus
implemented in our model. In the Markov model with
monthly cycles, events between 30 days and 1 year are
transformed to monthly percentages, which are also
used in the lifetime extrapolation in the model for
inoperable patients. In this cohort of inoperable
Table 1 Early and late mortality in the PARTNER trial
High-risk operable patients
Inoperable patients
Pivotal trial Cont. access Combined*
TAVI AVR p Value TAVI Stand. p Value TAVI Stand. TAVI Stand.
N 348 351 179 179 41 49 220 228
30-day mortality 3.4% 6.5% 0.07 5.0%y 2.8% 0.41 9.8% 2.1% 5.9% 2.7%
1-year mortality 24.2% 26.8% 0.44 30.7% 50.7% <0.001 34.3% 21.6% 31.4% 43.7%
Sources: high-risk operable patients: Smith et al
2; inoperable patients: pivotal trial: Leon et al
1; Continued Access: FDA.
4
*The weights are based on the number of participants in the pivotal and Continued Access trials.
yUncertainty surrounding mortality is modelled with b distributions with the same mean. The a parameter of these distributions equals the
number of events in the PARTNER randomised controlled trial. For example: 5% mortality on a total of 179 patients is reﬂected with
a b distribution with the a parameter being 9 (ie, 5% of 179¼9 patients) and the b parameter being 170 (ie, 179 9).
AVR, aortic valve replacement; Cont., continued; Stand., standard therapy; TAVI, transcatheter aortic valve implantation.
Figure 1 The TAVI Markov model. AVR, aortic valve
replacement; ST, standard therapy; TAVI, transcatheter aortic
valve implantation. The green square is a choice node, the red
dots are chance nodes and the blue triangles are end nodes.
Etc.: this indicates that if the patient survives, he goes to the
next cycle in the Markov model. In each monthly cycle, the
patient is again at risk of dying, being hospitalised, having other
events or no event.
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balloon aortic valvuloplasty, which was performed in
84% of patients, repeat TAVI in the TAVI group (1.7%)
and AVR which occurred in almost 10% of the standard
therapy group (see table 4 in the supplementary
appendix).
Aggregated cost data of 183 consecutive patients treated
in Belgium between June 2006 and June 2010 with the
Edwards SAPIEN valve (99 transfemoral and 84 trans-
apical) were obtained. The interventional procedure and
the device cost not (yet) being reimbursed, a cost of
€18000 and €1500, for the device and the procedure,
respectively, was assigned. This eventually resulted in
ac o s to fa b o u t€41000 and €50000 for transfemoral and
transapical TAVI (table 2). In the inoperable cohort, not
all patients assigned to TAVI actually underwent TAVI and
some patients in the standard therapy group received
AVR and/or balloon valvuloplasty. The cost of the initial
procedure was adjusted for this.
To calculate the cost of a surgical AVR, we obtained
data from 9213 hospital stays between 2004 and 2007.
This sample contains both older and younger patients
with a different severity of illness (grades 1e4). Since the
PARTNER study mainly includes older patients with
multiple comorbidities, older patients (>70) with
a higher severity of illness index (3 or 4) were selected,
resulting in an average AVR cost of €23749.
For the cost of balloon aortic valvuloplasty, the fee of
€488.75 is taken into account. Costs for repeat hospi-
talisations, minor or major stroke and TIA are based on
the APR-DRG costs for these categories as published
(publicly available at http://www.tct.fgov.be). It is
assumed that the cost of a speciﬁc event is the same
across all treatment groups. Finally, a theoretical follow-
up cost of about €43 per month and a drug cost of €21
per month (table 2), attributable to the number of
surviving patients, is included in the model. We assume
these monthly costs to be the same for all survivors in the
model.
Sensitivity and scenario analyses
The impact of uncertainty around all the model’s input
parameters on the results was modelled probabilistically.
The applied distribution depends on the type of vari-
able
5: transition probabilities (mortality or chance for
another event) and utilities are modelled as b distribu-
tions. This distribution is limited to the 0e1 scale and
reﬂects the possible outcomes for these variables. The
a parameter of this distribution equals the number of
events in the PARTNER RCT. The b parameter is
adjusted to equal the published percentage of events.
Strict correlation is imposed between the modelled
probabilities at 30 days and 1 year to avoid irrational
modelled outcomes. Relying on the central limit
theorem, TAVI and AVR costs are modelled as normal
distribution around the mean. Due to the large uncer-
tainty around follow-up costs, a uniform distribution
(650%) is applied. Finally, publicly available TCT cost
data are published with P5 and P95 values. For these cost
variables, g distributions reﬂecting the same mean, P5
and P95 values are modelled.
One thousand Latin Hypercube simulations are
performed. Outcomes with their surrounding uncer-
tainty are presented for IC, incremental effects (IE) and
the incremental cost-effectiveness ratio (ICER). Results
are shown on the cost-effectiveness plane and cost-
effectiveness acceptability curves. In our probabilistic
sensitivity analysis, rank correlation coefﬁcients are
calculated between the output values (the ICERs) and
the sampled input values to indicate the relative impor-
tance of variables and their uncertainty on the uncer-
tainty surrounding the outcomes.
One-way sensitivity analysis is performed on several
input variables. In this case, we start from the published
pivotal trial data because no full details of the Continued
Access trial were provided by the study sponsor.
Including the results on mortality from the Continued
Access trial is modelled as one of the scenarios and is
considered as base case since there is no good reason to
exclude the results from this trial with the same protocol
as the pivotal trial. The following scenarios are modelled
for high-risk operable patients: TAVI device cost of
€10000 and an optimistic QoL improvement of 0.1
during the whole ﬁrst year. In the model for inoperable
patients, the scenarios are restricted 3-year time horizon,
no discounting or discount rate of 5% for both costs and
effects, no adjustment of TAVI and standard therapy
costs for actually performed treatment, inclusion or
exclusion of events in the model (major/minor stroke or
TIA) and TAVI device cost of €10000. One speciﬁc
subgroup scenario analysis is added for mortality risk
reduction in medically versus anatomically inoperable
patients. Although the reduction in mortality is observed
in both subgroups in the pivotal trial, it is larger in the
latter subgroup (absolute 27.9%) than in the former
subgroup (absolute 17%). Results of these analyses are
presented on a tornado graph.
RESULTS
Based on the results of the PARTNER trial in high-risk
operable patients, the incremental survival beneﬁt of
TAVI in comparison with AVR is minimal, on average
0.03 (95% CI  0.01 to  0.07) quality-adjusted life-years
(QALYs). In combination with substantial ICs (on
average €20397, 95% CI 18278 to 22617), this results in
very high ICERs of about €750000 per QALY gained.
This contrast between minimal gains and substantial
expenses is shown on the cost-effectiveness plane in the
supplementary appendix (ﬁgure 5). Even the scenario
analyses with a price reduction of the TAVI device cost to
€10000 or an assumed QoL improvement of 0.1 during
the whole ﬁrst year results in relatively high ICERs, that
is, on average €455000 and €205000 per QALY gained,
respectively.
For inoperable patients, the IC of TAVI compared with
standard therapy is about €33200 with an IE on survival
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becomes about €42600 per LYG or on average €44900
per QALY gained (see details on IC, IE and ICERs in
table 5 in the supplementary appendix and ﬁgure 2,
top). The cost-effectiveness acceptability curve (ﬁgure 2,
bottom) indicates that a willingness-to-pay for a QALY of
more than €42000 is needed to have about 50% chance
the intervention is considered cost-effective in this
cohort of patients.
The probabilistic sensitivity analysis shows that the most
important stochastic variables in the model are the
mortality and utility at 12 months in the TAVI group
Table 2 Overview of cost data
Variable Mean Uncertainty Source
TAVI (high-risk operable patients)
TF €40917 Normal (mean: 40917; SD
mean 1204)
Gov. Health Ins. Database*
TA €49799 Normal (mean: 49799; SD
mean 1994)
Gov. Health Ins. Database*
All €43571y
TAVI (inoperable patients) €40057z
Standard therapy €3170x
AVR €23749{ Normal (mean: 23749; SD
mean 191)
Gov. Health Ins. Database**
Balloon aortic valvuloplasty €489yy Fixed fee Belgian Nomenclature code
Repeat hospitalisation €5983 Gamma (mean: 5983; P5:
1339; P95: 15596)
TCT, APR-DRG 194 (Heart
failure)
Stroke TCT, APR-DRG 045 (CVA
with stroke)
Minor €4679zz Gamma (mean: 3292; P5:
932; P95: 6842)
Minor
Gamma (mean: 6066; P5:
1574; P95: 17285)
Moderate
Major €12493zz Gamma (mean: 9593; P5:
1630; P95: 27526)
Major
Gamma (mean: 15392; P5:
2631; P95: 40079)
Extreme
TIA €3946 Gamma (mean: 3946; P5:
974; P95: 9942)
TCT, APR-DRG 047 (TIA)
Follow-up fees €43.2/monthxx Uniform (650%) Expert opinion
Follow-up drugs €20.5/month{{ Uniform (650%) Gov. Health Ins. Database*
*IMA data.
yThe weighted average of TF and TA TAVI cost. The weight is determined by the number of TF and TA patients in the PARTNER trial, being
244 and 104, respectively.
zIn the PARTNER trial, of the 179 patients assigned to TAVI, six (3.4%) did not receive a transcatheter heart valve: two patients died before the
scheduled implantation, transfemoral access was unsuccessful in two patients and the intraprocedural annulus measurement was too large in
two patients.
1 Similarly, in our model, the complete TAVI procedure cost was assigned to 96.6% (173/179) of patients, 1.1% were assigned no
costs because they died before the procedure and 2.2% was assigned the procedure cost without the TAVI device cost of €18000. This results
in an average cost of €40057.
xIn the PARTNER trial, 12 of the patients who were assigned to standard therapy (6.7%) underwent aortic-valve replacement, ﬁve (2.8%)
underwent placement of a conduit from the left ventricular apex to the descending aorta plus aortic valve replacement (AVR) and four (2.2%)
underwent TAVI at a non-participating site outside the USA.
1 Therefore, the cost of AVR is assigned to 9.5% (6.7% + 2.8%) of the patients and
the TAVI cost to 2.2%. This results in an additional cost of €3170 in the standard therapy group.
{The cost was calculated for patients (N¼4811) older than 70 and an SOI index of 3 or 4. If this was restricted to patients (N¼1506) older than
80 with an SOI index of 3 or 4, the cost remained the same (€23772).
**TCT data. Year of pricing: 2006e2010 for TAVI and standard therapy; 2008 for all TCT-based APR-DRG prices; 2004e2007 for AVR. Due to
the incremental character of the analysis, price adjustments would have no substantial inﬂuence on results. Furthermore, the analysis in high-
risk operable patients showed that the result is determined by the (lack of) incremental effect of TAVI versus AVR.
yyThe fee is included explicitly in the control group. If this procedure would include a hospitalisation, then these costs are already included in the
model as ‘repeat hospitalisation’. In the TAVI group, to avoid double counting, this cost is not included separately since it is part of the TAVI
procedure, and thus, the cost is already included in the analysis.
zzFor stroke, the TCT makes a distinction between four categories (minor, moderate, major and extreme). The former two categories were
reclassiﬁed as minor stroke and the latter two as major stroke.
xxThe follow-up costs included the following: four consultations cardiologist (€34.5/unit), four ECG (€17.18/unit); one echo, full transthoracal
ultrasound bilan of the heart (€67.16/unit); three echo, repetition within the calendar year of full transthoracal ultrasound bilan of the heart
(€67.16/unit) or limited transthoracal ultrasound bilan of the heart (€38.75); one full transoesophageal ultrasound bilan of the heart (€113.01/
unit) or limited transoesophageal ultrasound bilan of the heart (€58.12/unit).
{{The selected drugs were the following: acenocoumarol, aspirin, clopidogrel, dalteparin, danaparoid, enoxaparin, fenprocoumon, heparin,
nadroparine, ticlopidine, tiroﬁban and warfarin. The real-world expenditures in the Belgian Edwards TF TAVI group was €246 per year or €20.5
per month. For more details, we refer to the full HTA report.
6
APR-DRG, All Patient Reﬁned Diagnosis Related Groups; AVR, aortic valve replacement; Gov. Health Ins. Database, Governmental Health
Insurance Database; IMA, Intermutualistic Agency; SOI, severity of illness; TAVI, transcatheter aortic valve implantation; TCT, Belgian
Technical Cell; TIA, transient ischaemic attack.
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6
The one-way sensitivity analyses indicate the importance
of the extrapolation assumption. With a 3-year time
horizon, the ICER of the pivotal PARTNER trial almost
doubled (from €37400 per QALY to €71600 per QALY).
Finally, the anatomically inoperable patients have a more
favourable ICER than the medically inoperable patients
(ﬁgure 6 in the supplementary appendix).
DISCUSSION
This is the ﬁrst non-industry-based study that calculates
the cost-effectiveness of TAVI, based on the results of
a randomised controlled trial. The cost-effectiveness of
TAVI is highly dependent on the patient population
under consideration. In high-risk operable patients,
TAVI and surgery are associated with similar mortality
rates at 1 year and produce similar improvements in
cardiac symptoms. However, the twice as high rate of
stroke after TAVI as compared with surgery (8.3% vs
4.3% at 1 year) is problematic. From a medical point of
view, TAVI might be considered as an alternative to
surgery for high-risk patients who are willing to accept
this higher risk of stroke.
7 From an economic point of
view, the less invasive nature of the TAVI procedure does
not weigh against the extra costs. With an average ICER
of about €750000 per QALY (ﬁgure 3), it is hard to
defend a reimbursement for TAVI in high-risk operable
patients as an efﬁcient use of limited resources. This can
be altered if TAVI costs become similar to those of AVR.
The long-term consequences of stroke on both QoL and
costs should also not be underestimated and would
probably worsen the ICER of TAVI.
In inoperable patients, TAVI signiﬁcantly reduces the
rate of death from any cause as compared with a non-
surgical approach (absolute risk reduction of 12.3% in
combined pivotal and Continued Access trial). TAVI also
signiﬁcantly improves cardiac symptoms and reduces the
need for repeat hospitalisations. Stroke rate at 1 year,
however, was twice as high in TAVI patients compared
with those treated non-surgically (10.6% vs 4.5%). From
a medical point of view, the overall beneﬁt of TAVI in
those patients seems to outweigh the risks, and there-
fore, it may be appropriate to consider and discuss TAVI
with patients who cannot be operated.
For inoperable patients, combining the mortality data
from both the pivotal and Continued Access trial results
in an ICER of about €45000 per QALY (ﬁgure 3). In
most countries, as well as in Belgium, there is no explicit
ICER threshold. Only NICE (National Institute for
Health and Clinical Excellence) has explicitly
mentioned this in their Guide to the Methods of Tech-
nology Appraisal.
8 Applying NICE’s threshold values of
£20000 (£1¼€1.14, 25 August 2011) and £30000 per
QALY, results in a 9.2% and 36.7% chance, respectively, Figure 2 Cost-effectiveness plane (top) and cost-
effectiveness acceptability curve (bottom) for TAVI in
inoperable patients. The green curve on the cost-effectiveness
plane is the 95% conﬁdence ellipse.
Figure 3 TAVI’s cost-effectiveness. ICER, incremental cost-
effectiveness ratio; QALY, quality-adjusted life-year. The x-axis
indicates the operability of patients. There is an overlap
between medically inoperable and high-risk operable patients.
Anatomically inoperable patients are readily identiﬁable. For
high-risk operable patients, the ICERs are very high (€750000
per QALY). For inoperable patients, the ICER was on average
€45000 per QALY. Within the latter category, ICERs are better
for anatomic inoperable patients and worse for medical
inoperable patients.
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vention. This rather is an optimistic estimate due to
several factors: the unbalanced patient characteristics in
the PARTNER trial in favour of the TAVI group (see next
paragraph), the lifelong extrapolation assumption on
survival (see FDA remark in the supplementary
appendix (ﬁgure 7)), keeping QoL at a high level in the
long term in this ageing population, and the possible
long-term consequences and costs of stroke.
In the PARTNER trial, baseline characteristics of
inoperable patients were unevenly distributed among
the two study groups, most if not all imbalances
favouring survival in the TAVI-treated patients. The
logistic EuroSCORE was higher in the control arm (30.4
vs 26.4, p¼0.04), and both chronic obstructive pulmo-
nary disease (52.5% vs 41.3%) and atrial ﬁbrillation
(48.8% vs 32.9%) were statistically signiﬁcantly (p<0.05)
more prevalent. Frail patients (28% vs 18.1%, p¼0.09)
were also over-represented. In general, patients who are
inoperable due to comorbidities were over-represented
in the control arm. The PARTNER study protocol stip-
ulates that both medical and anatomic conditions may
lead to the surgeons’ conclusion of inoperability and
that the surgeons’ consult notes shall specify the medical
or anatomic factors.
9 Patients with coexisting anatomic
conditions (extensively calciﬁed aorta, deleterious
effects of chest-wall irradiation and chest-wall deformity)
were better represented in the TAVI group than in the
control group (29.6% vs 20.7%, p¼0.05). These
anatomically inoperable patients probably have a better
prognosis and QoL after remediating the aortic valve
stenosis. Because of the imbalance in patient character-
istics and the possibly better prognosis, this one
subgroup analysis for this speciﬁc patient characteristic
was asked to the study sponsor.
The absolute mortality gain after TAVI was an absolute
17 percentages in the non-anatomical inoperable group
versus an absolute 27.9 percentages in the anatomical
inoperable group. This results in an improved ICER for
the latter group (about €11000 per QALY lower) and
vice versa for the other group (about €5000 per QALY
higher). Results of this subgroup analysis were only
provided for the pivotal trial and for the mortality end
point. Further reﬁnement of the cost-effectiveness
calculation is only possible if further details for the whole
population (pivotal and Continued Access) and for all
relevant outcomes (mortality, events and QoL) are made
available by the study sponsor. With currently best avail-
able data, the performed analyses show that, if one is
willing to pay the considerable amount for the QALYs
gained, reimbursement of TAVI could in the ﬁrst place
focusonthissubgroupofanatomical inoperablepatients.
The clinical differentiation of PARTNER high-risk
operable from inoperable patients based on objective
parameters is not straightforward and essentially based
on the clinical feeling of the physicians involved.
Comparing the patient characteristics between high-risk
operable and inoperable patients in the PARTNER trial
reveals there are no clear differences in the clinical
baseline characteristics of the two populations, with
exception of anatomical prohibitive conditions.
6 While
high-risk operable patients should be excluded from
TAVI treatment on medico-economic grounds, physi-
cians can, however, subjectively label them as inoperable
patients. Belgian registry data showed that a substantial
part of the Belgian TAVI patients have better character-
istics (lower NYHA class and less coronary artery disease
and previous CABG) than PARTNER high-risk operable
and inoperable patients.
6 Also the German registry has
shown that many patients received TAVI, although their
valves could also have been replaced by open surgery.
10
Broadening of the population to lower risk populations
might result in worse outcomes. To avoid waste of
resources, artiﬁcially including patients should be
avoided at all times. Anatomically inoperable patients,
who beneﬁt most from the intervention, can easily be
distinguished from other patients (ﬁgure 3).
It should be noted that the evidence from the
PARTNER trial for inoperable patients only applies to
the transfemoral approach. Although the FDA proposed
to do so, the PARTNER study sponsor did not include
a transapical arm in inoperable patients (see ﬁgure 4 in
the supplementary appendix).
4 In high-risk operable
patients, a subgroup analysis suggests that the transapical
approach is not inferior to surgery but doubles the
stroke risk. Recently, the results from the STACCATO
trial, an independent RCT of transapical TAVI in oper-
able elderly patients have been presented.
11 The primary
end point (30-day all-cause mortality, major stroke and/
or renal failure) was reached in 5/34 TAVI and 1/36
surgically treated patients, and the study was prematurely
terminated after advice from the Data Safety Monitoring
Board. Given the fact that operative risk estimation is
a highly subjective matter, it is as yet unclear to what
extent the operative risk of patients enrolled in STAC-
CATO is different from that of PARTNER patients or
from patients currently treated all over Europe. These
observations once more put into question the appro-
priateness for the European regulators granting the
transapical Sapien valve a CE label in 2007.
12 It also
shows the importance of performing high-quality rand-
omised trials with clinically relevant endpoints prior to
granting marketing approval of innovative high-risk
devices.
12
The contrast between the USA and EU regulation is
striking. Evidence of clinical efﬁcacy is required before
market entry in the USA but not in Europe.
12 This is also
the case with TAVI. In the USA, the PARTNER-US study
design is an RCT to demonstrate efﬁcacy. In contrast, in
Europe, the PARTNER-EU and other studies are mere
registries with no control group. Despite European data
from thousands of patients, it remains unclear from
these registries for whom the intervention is beneﬁcial
due to a lack of a proper research design. For innovative
high-risk devices, the future EU Device Directive
should move away from requiring clinical safety and
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that demonstrate ‘clinical efﬁcacy’.
12
Not publishing negative or prematurely terminated
studies is problematic for assessing clinical efﬁcacy and
supporting rational decision making. Manufacturers
should reveal all relevant or requested information to
health technology assessment bodies. If this does not
work on a voluntary basis, then, policy makers should
have the courage to take more drastic measures. For
example, government could refuse to take a reimburse-
ment decision as long as not all relevant data are
provided. The German Institute for Quality and Efﬁ-
ciency in Health Care (IQWiG) assessment report on the
antidepressant reboxetine has shown this can be a very
effective measure: Pﬁzer did not submit a complete list of
unpublished trials as requested by IQWiG. IQWiG
therefore issued the preliminary conclusion that because
of the high risk of publication bias, no meaningful
assessment of reboxetine was possible and thus no
beneﬁt of the drug could be proved.
13 Pﬁzer then
decided to provide most of the missing data and the
subsequent assessment showed that, overall, reboxetine
had no beneﬁt.
14e16 Unfortunately, several other exam-
ples of publication bias exist that could have inﬂuenced
policy recommendations and decisions if full informa-
tion was available. The non-availability of complete
information is, as mentioned in a BMJ editorial, ‘a
disservice to research participants, patients, health
systems, and the whole endeavour of clinical medicine’.
17
CONCLUSIONS
Based on currently available data, it is not recommended
to reimburse TAVI for high-risk operable patients.
Although the intervention is less invasive, patients have
no survival beneﬁt after 1 year, the risk of stroke is
doubled and the costs are signiﬁcantly higher. In inop-
erable patients, a distinction should be made between
medically and anatomically inoperable patients. In the
former group, TAVI treatment is palliative and the
patient’s life expectancy and QoL remain limited due to
comorbidities that persist after correction of the aortic
stenosis. Anatomically inoperable patients are likely to
beneﬁt most from TAVI since they not necessarily have
debilitating comorbid conditions. In those patients, the
ICER is also the most favourable. If decision makers are
willing to reimburse the relatively high price for TAVI,
then it is recommended to focus in the ﬁrst place on this
clinically readily identiﬁable subgroup.
Finally, the study sponsor should be more willing to
share all relevant data in due time, that is, before
important policy decisions are taken. Both positive and
negative study results providing details on all relevant
outcomes (mortality, adverse events and QoL) for the
most important subgroups should be revealed. This will
enable more balanced evaluations and well-founded
policy recommendations. Payers should insist to have
full information before taking reimbursement decisions.
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